Warning Letter — MantroForce
The FDA's Center for Drug Evaluation and Research issued a Warning Letter to MantroForce on June 17, 2026, regarding compliance issues identified by the agency.
MantroForce, regulatory compliance officers, and quality assurance departments managing products under CDER jurisdiction.
The issuance of a Warning Letter by CDER indicates that the agency has identified significant violations of the Federal Food, Drug, and Cosmetic Act. For regulatory professionals, this signal suggests that the company's current marketing, manufacturing, or distribution practices have failed to meet federal standards, potentially leading to further enforcement actions such as seizures or injunctions if not remediated.
Regulatory teams should immediately audit all product listings and marketing materials to ensure no unauthorized drug claims are being made. Quality and Compliance departments should review the specific violations cited in the full letter to ensure all distribution and labeling practices align with CDER requirements.
FDA Warning Letter issued to: MantroForce. 06/17/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mantroforce-729021-06172026
Open in openFDA / FDA.gov